Life Science

AI Tailored Precision for Clinical Development

Driven by our quantitative imaging biomarkers, regulated software and clinical expertise, our bespoke end-to-end services for Pharma, Biotech and Medtech provide tailored support throughout the full lifecycle of clinical development, from concept to execution, medical affairs and beyond.

Core Partnership Areas
‍
Gray circle with white number 01 centered inside.
Retrospective clinical trials

Retrospective
Clinical Trials

Post-hoc or exploratory analysis of existing clinical trial datasets to uncover new findings and to test or validate existing results.

Light gray circle with the number 02 in white inside.
Prospective clinical trials

Prospective
Clinical Trials

Prospective analysis, including of baseline cohort characterisation and follow up assessment through quantitative endpoints for safety, efficacy and MOA.

Light gray circle with white number 03 centered inside.
Real-world datasets

Real World
Datasets

Brainomix or sponsor-provided Real-World data to test, validate or inform study findings and clinical development strategy.

Light gray circle with white number 04 centered inside.
Bespoke development of software or biomarkers

Bespoke Development of Software or Biomarkers

Creation and validation of novel digital biomarkers and bespoke software for Life Science partners using Brainomix- or Sponsor provided data.

Light grey circle with white number 05 centered inside.
Supporting treatment decisions

Supporting
Treatment Decisions

Brainomix regulatory cleared software can be used as part of go-to-market strategies to support appropriate treatment decisions in the Real World.

Light gray circle with the number 06 centered in white text.
Expert clinical advisory

Expert
Clinical Advisory

Design and Review of Protocols, Selection of Endpoints, Interpretation and Dissemination of Study Results.

Life Science Partners. Brainomix's services support a wide array of Life Science companies from across the globe, including start-ups, biotech, large pharma partners, and medical device companies.
Some of Our Partners:
AstraZenecaBridgeBio TherapeuticsBoehringer IngelheimEndeavor BioMedicinesLumosa TherapeuticsArgenica TherapeuticsRemedy PharmaceuticalsMedtronicAvalyn PharmaClario
AstraZenecaBridgeBio TherapeuticsBoehringer IngelheimEndeavor BioMedicinesLumosa TherapeuticsArgenica TherapeuticsAbbVieMedtronicRemedy PharmaceuticalsAvalyn PharmaClario
Service Offering
Work with Brainomix today to support your clinical development.
01
Specialty imaging support for multi-center clinical trials
02
AI-enhanced cohort evaluation for eligibility adherence and safety assessments
03
Proprietary biomarkers, bespoke development services, and Core Lab analytics
04
Medical and imaging consulting support for trial design, execution, and data interpretation
05
Customizable patient selection software to enrich and standardize study populations
06
Seamless integration into leading CROs to streamline clinical trial and imaging workflows
Brainomix stroke imaging biomarkers on a smartphone
20+
Leading Life Science partners benefitting from Brainomix insights and expertise.
Brain scan processed by Brainomix on a smartphone
3.5 Mil
More than 3.5 million scans processed by Brainomix
Hospital stretcher in a corridor
35+
Regulatory Clearances for Clinical Use (FDA, CE, ANVISA, and more)
Clinician reviewing lung CT analysis in a hospital
350+
Hospital Installations
Brainomix imaging biomarkers shown on a brain scan
40+
Imaging Biomarkers Available
Radcliffe Camera, Oxford, home of Brainomix
20+
Countries with Brainomix deployed
Researcher analysing brain scan data for a clinical trial
15
Clinical trials
Doctor discussing scan results with patients
5
Phase III clinical trials
AI-Powered Quantitative Imaging Biomarkers
Imaging Biomarkers
ASPECTS imaging biomarker on a CT brain scan
Modality: CT
Automated measure of ASPECTS
‍
Clot location imaging biomarker on a CT scan
Modality: CTA
Automated detection and localization of LVO
‍
Collateral volume imaging biomarker on a CTA scan
Modality: CTA
Automated quantification of collaterals
‍
Ischemic core imaging biomarker on a brain scan
Modality: NCCT, MRI
Automated measure of ischemic core, voxel-by-voxel
‍
Edema and swelling imaging biomarker on a brain scan
Modality: NCCT, MRI
Automated measure of edema/swelling
‍
Perfusion imaging biomarker on a brain scan
Modality: CTP, MRI
Automated measure of perfusion metrics
‍
Blood volume imaging biomarker on a brain scan
Modality: NCCT, MRI
Automated measure of blood volume
‍
Imaging Biomarkers
Lung imaging biomarker on a 3D lung CT rendering
Modality: CT
Measure of total lung volume which correlates with lung physiology measures such as FVC
Lung fibrosis imaging biomarker validated in the INBUILD trial
Modality: CT
Validated in INBUILD® Phase III Study of Ofev®
‍
Lung disease extent imaging biomarker on CT
Modality: CT
Shown to prognosticate for mortality and disease progression. Validated in INBUILD® Phase III Study of Ofev®
*Some biomarkers and visualizations may not be cleared for clinical use
Clinical Trial Case Studies
AstraZeneca
AstraZeneca
Trial: NCT01629667
Phase: II
Indication: Idiopathic Pulmonary Fibrosis
Treatment: tralokinumab  

Brainomix and AstraZeneca partnered to analyze Phase 2 tralokinumab clinical trial data, leveraging Brainomix’s AI-powered software and biomarkers to uncover novel insights. The output of this partnership has been published in the AJRCCM.
“As key components in AstraZeneca’s strategy to bring new medicines to patients faster and more effectively, data science and AI are transforming R&D. Our collaboration with Brainomix helped us to expand our understanding of the potential that innovative AI approaches can bring to improving the design of clinical trial for patients with Interstitial Lung Disease.”
Dr. Kristoffer Ostridge
Head of Experimental Medicine, AstraZeneca
Boehringer Ingelheim
Boehringer Ingelheim
Trial: DROP-FPF (NCT07201922)
Phase: III
Indication: Pulmonary Fibrosis
Treatment: nerandomilast (Jascayd®)

In an industry-first, Boehringer Ingelheim selected Brainomix AI fibrosis biomarkers as the co-primary imaging endpoint for its Phase III trial in pulmonary fibrosis to provide a quantifiable measure of disease progression alongside FVC, a traditional measure of lung function.
“Our goal is simple but profound: learn whether acting earlier can change outcomes for families facing these devastating diseases. Using Brainomix’s advanced HRCT algorithm to define meaningful progression, we aim to generate insights that could transform how and when to intervene.”
Martin Beck
Senior VP and Head of Inflammation, Boehringer Ingelheim
Remedy Pharmaceuticals
Remedy Pharmecuticals
Trial: CHARM (NCT02864953)
‍Phase: III
‍Indication: Large Hemispheric Infarction
‍Treatment: Glyburide

For its Phase 3 study on Glyburide (CIRARA) in large hemispheric infarction, Remedy partnered with Brainomix to perform an analysis of both imaging and clinical data. Brainomix quantified baseline and follow-up images of patients who had been assessed using NCCT, CTP, and MRI modalities using advanced multi-modal AI imaging biomarkers.
“Brainomix imaging and data analysis capabilities really allowed us to explore our data more deeply and clearly than we previously had thought possible. Our partnership was highly productive, insightful and valuable in informing our ongoing clinical development”
Sven Jacobsen
CEO Remedy Pharmecuticals
Argenica Therapeutics
Argenica Therapeutics
Trial: SEANCON (ACTRN12623001110673)
Phase: II
Indication: Acute Ischemic Stroke
Treatment: ARG-007

Brainomix and Argenica Therapeutics have partnered on the ARG-007-002 study. Brainomix AI expertise and analytics are supporting the clinical development of ARG-007 through robust characterization of treatment effect and identification of responsive phenotypes.
“Brainomix expertise and AI-enhanced imaging allows to do more with our clinical trial data, giving us a better indication of treatment effect and allowing us to dig into key biomarkers.”
Liz Dallimore
CEO Argenica Therapeutics
Ross Stewart, Associate Director, Life Sciences, Brainomix
“I have been proud to contribute to our Life Science Partnerships during my time at Brainomix. Our approach is critically focused on delivering sustainable, mutually aligned value to our Partners, and I am confident in our capabilities to work within this ecosystem to make a positive impact on patient outcomes.”
Ross Stewart
Associate Director, Life Sciences
Dr Kira Schützenhofer, Life Sciences business development, Brainomix
Kira joined Brainomix in 2025 as part of the Life Sciences business development team. Before transitioning into industry, she completed a PhD in Molecular Cell Biology at the University of Oxford, studying tumour responses to targeted therapies. At Brainomix, she combines her scientific background with her interest in driving innovation to help forge partnerships that translate AI-driven insights into better clinical outcomes.
Kira Schützenhofer, PhD
Business Development Associate

Ready to transform your clinical development journey?

Join 20+ leading Life Science partners already benefitting from Brainomix insights and expertise.